Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
PALO ALTO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and
commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the out-of-pocket costs for its product portfolio for commercially insured
patients is expected to be capped at $25 monthly, with certain eligible patients paying as low as $0. This applies to the Company's postherpetic neuralgia pain product, ZTlido, migraine product,
ELYXYB, and gout flare prophylaxis product, Gloperba, which is expected to launch in the first half of 2024. Scilex has made significant investments to improve patient affordability and access to
its products and continues to build on the Company's commitment to provide non-opioid pain management products to patients.
Scilex has been working with its co-pay savings card adjudicators to resolve the recent breakdown of processing of insurance claims by Change Healthcare, following a cyber-attack on Change Healthcare. Scilex is aware of the impact this disruption has had on its patients and customers and has worked diligently to resolve the issue. Starting today, co-pay savings card processing for ZTlido is expected to be restored to normal operations.
Scilex believes that high deductibles and copays shouldn’t prevent anyone from receiving the medications they need. Scilex co-pay programs is designed to help patients reduce their co-pays and out-of-pocket costs for their medication. Our program partners with various assistance programs to help make a patient’s medication affordable.
For more information on Scilex Holding Company, refer to www.scilexholding.com
For more information on ZTlido including Full Prescribing Information, refer to www.ztlido.com.
For more information on ELYXYB, including Full Prescribing Information, refer to www.elyxyb.com.
For more information on Gloperba, including Full Prescribing Information, refer to www.gloperba.com.
Lesen Sie auch
https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
About Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, expected to launch in the first half of 2024.